Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-lin...
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Eduardo Garc ía Natalie Ayoub Krishnansu S Tewari Source Type: research
Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
CONCLUSION: Our nationwide registry-based study demonstrated that the incidence of ovarian carcinosarcoma increased from 1999 to 2018 in Korea. Patients with advanced-stage disease and older age (≥50 years) had poorer survival outcomes.PMID:38072401 | DOI:10.3802/jgo.2024.35.e31 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Hyeong In Ha Ji Hyun Kim Jiwon Lim Yong Jung Song Young-Joo Won Myong Cheol Lim Source Type: research
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
CONCLUSION: Linc01194 can promote the expression of downstream protein SOX2 through binding to IGF2BP1, thus promoting the occurrence and development of EC.PMID:38072399 | DOI:10.3802/jgo.2024.35.e21 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Zhenghao Huang Fan Shen Jingwen Chen Bumin Xie Xi Chen Yang Zhao Shuo Chen Source Type: research
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-lin...
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Eduardo Garc ía Natalie Ayoub Krishnansu S Tewari Source Type: research
Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
CONCLUSION: Our nationwide registry-based study demonstrated that the incidence of ovarian carcinosarcoma increased from 1999 to 2018 in Korea. Patients with advanced-stage disease and older age (≥50 years) had poorer survival outcomes.PMID:38072401 | DOI:10.3802/jgo.2024.35.e31 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Hyeong In Ha Ji Hyun Kim Jiwon Lim Yong Jung Song Young-Joo Won Myong Cheol Lim Source Type: research
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
CONCLUSION: Linc01194 can promote the expression of downstream protein SOX2 through binding to IGF2BP1, thus promoting the occurrence and development of EC.PMID:38072399 | DOI:10.3802/jgo.2024.35.e21 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Zhenghao Huang Fan Shen Jingwen Chen Bumin Xie Xi Chen Yang Zhao Shuo Chen Source Type: research
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-lin...
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Eduardo Garc ía Natalie Ayoub Krishnansu S Tewari Source Type: research
Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
CONCLUSION: Our nationwide registry-based study demonstrated that the incidence of ovarian carcinosarcoma increased from 1999 to 2018 in Korea. Patients with advanced-stage disease and older age (≥50 years) had poorer survival outcomes.PMID:38072401 | DOI:10.3802/jgo.2024.35.e31 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Hyeong In Ha Ji Hyun Kim Jiwon Lim Yong Jung Song Young-Joo Won Myong Cheol Lim Source Type: research
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
CONCLUSION: Linc01194 can promote the expression of downstream protein SOX2 through binding to IGF2BP1, thus promoting the occurrence and development of EC.PMID:38072399 | DOI:10.3802/jgo.2024.35.e21 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Zhenghao Huang Fan Shen Jingwen Chen Bumin Xie Xi Chen Yang Zhao Shuo Chen Source Type: research
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-lin...
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Eduardo Garc ía Natalie Ayoub Krishnansu S Tewari Source Type: research
Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
CONCLUSION: Our nationwide registry-based study demonstrated that the incidence of ovarian carcinosarcoma increased from 1999 to 2018 in Korea. Patients with advanced-stage disease and older age (≥50 years) had poorer survival outcomes.PMID:38072401 | DOI:10.3802/jgo.2024.35.e31 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Hyeong In Ha Ji Hyun Kim Jiwon Lim Yong Jung Song Young-Joo Won Myong Cheol Lim Source Type: research
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
CONCLUSION: Linc01194 can promote the expression of downstream protein SOX2 through binding to IGF2BP1, thus promoting the occurrence and development of EC.PMID:38072399 | DOI:10.3802/jgo.2024.35.e21 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Zhenghao Huang Fan Shen Jingwen Chen Bumin Xie Xi Chen Yang Zhao Shuo Chen Source Type: research
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-lin...
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Eduardo Garc ía Natalie Ayoub Krishnansu S Tewari Source Type: research
Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
CONCLUSION: Our nationwide registry-based study demonstrated that the incidence of ovarian carcinosarcoma increased from 1999 to 2018 in Korea. Patients with advanced-stage disease and older age (≥50 years) had poorer survival outcomes.PMID:38072401 | DOI:10.3802/jgo.2024.35.e31 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Hyeong In Ha Ji Hyun Kim Jiwon Lim Yong Jung Song Young-Joo Won Myong Cheol Lim Source Type: research
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP1
CONCLUSION: Linc01194 can promote the expression of downstream protein SOX2 through binding to IGF2BP1, thus promoting the occurrence and development of EC.PMID:38072399 | DOI:10.3802/jgo.2024.35.e21 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - December 10, 2023 Category: OBGYN Authors: Zhenghao Huang Fan Shen Jingwen Chen Bumin Xie Xi Chen Yang Zhao Shuo Chen Source Type: research
